IlvaRupenthal Profile Banner
Ilva Rupenthal Profile
Ilva Rupenthal

@IlvaRupenthal

Followers
287
Following
197
Media
6
Statuses
94

Associate Professor and Director of the Buchanan Ocular Therapeutics Unit, University of Auckland

Auckland, New Zealand
Joined March 2018
Don't wanna be here? Send us removal request.
@BOTU_NZ
Buchanan Ocular Therapeutics Unit
3 years
And another one - well done, Lola and team πŸ‘ Very interesting review on he role of the NLRP3 inflammasome in the eye and brain during ageing. https://t.co/yHdCmbGs1g
0
1
3
@BOTU_NZ
Buchanan Ocular Therapeutics Unit
3 years
And another one by Agarwal et al., published online on the same day! Priyanka, you are on a roll πŸ‘ Preclinical characterization of water-free cyclosporine eye drops - fa...
0
1
5
@BOTU_NZ
Buchanan Ocular Therapeutics Unit
3 years
A nicely written and thought provoking review article by Agarwal et al. (and my 100th publicationπŸŽ‰ ). Well done, Priyanka πŸ‘ Non-aqueous formulations in topical ocular drug delivery – a paradigm ...
0
1
3
@BOTU_NZ
Buchanan Ocular Therapeutics Unit
3 years
Learn from visiting Professor Conny Keck about particle size characterization.
0
1
2
@BOTU_NZ
Buchanan Ocular Therapeutics Unit
3 years
A warm welcome to our international academic visitors πŸ‡©πŸ‡ͺπŸ‡§πŸ‡·πŸ‡©πŸ‡ͺ. We are excited to investigate novel ocular drug delivery solutions with you over the next few months.
0
1
4
@BOTU_NZ
Buchanan Ocular Therapeutics Unit
3 years
A long time in the making. Many thanks to everyone who contributed to this paper. Preparation and Characterisation of a Cyclodextrin-Complexed Mānuka Honey Microemulsion for Eyelid Application https://t.co/dhg57sgDYf #mdpipharmaceutics via @MDPIpharma
Tweet card summary image
mdpi.com
Honey has been widely purported as a natural remedy due to its antimicrobial and anti-inflammatory effects. In recent years, several studies have suggested that the considerably high methylglyoxal...
0
1
5
@IlvaRupenthal
Ilva Rupenthal
4 years
Amazing to see how many articles have been published in the area of ocular drug delivery in @DDTReMedia over the past 5 years. I really enjoyed compiling this collection with my colleague Priyanka Agarwal.
@DDTReMedia
Drug Delivery and Translational Research
4 years
Check out the first @DDTReMedia collection, featuring ocular drug delivery. We thank Drs. Priyanka Agarwal and @IlvaRupenthal for the excellent editorial role on this collection! @MariaJ_Alonso @CRSScience @CRS_FG_Ocular @CRS_YSC #ocular #drugdelivery https://t.co/1IHRRDWo3z
0
0
4
@BOTU_NZ
Buchanan Ocular Therapeutics Unit
4 years
Awesome video publication of a novel retinal culturing technique which can be used to investigate retinal disease mechanisms as well as test novel drug molecules to treat such disease. Well done Charisse and the team!
0
2
6
@IlvaRupenthal
Ilva Rupenthal
4 years
Well done, team!
@BOTU_NZ
Buchanan Ocular Therapeutics Unit
4 years
Awesome review article by Avik Shome and the team. Really looking forward to the outcomes of the preclinical study we are currently conducting in this area. Blocking the inflammasome: A novel approach to treat uveitis
0
0
3
@IlvaRupenthal
Ilva Rupenthal
4 years
Happy to join the editorial board of the New Frontiers in Drug Delivery journal as Associate Editor for the Ophthalmic Drug Delivery section led by Professor Francine @CohenBehar.
@FrontDrugDDS
Frontiers in Drugs Portfolio
4 years
Led by Prof. @BraydenDavid of @ucddublin, @Frontiersin #DrugDelivery aims to develop new methods of delivering targeted drugs into the body through utilizing emerging technologies such as AI and 3D printing. Learn more ⬇
1
2
13
@MDPIpharma
Pharmaceutics MDPI
5 years
#MDPIPharmaceuticsπŸ“— "Formulation Considerations for the Management of Dry Eye Disease" by Priyanka Agarwal et al. Full paper at https://t.co/uLWTCmaB5o
0
2
3
@BOTU_NZ
Buchanan Ocular Therapeutics Unit
5 years
OTE1 was a great success. Thanks again to our amazing speakers Shenton Chew, Graham Reeves, Divya Perumal and Hussain Patel as well as our sponsors Device Ophthalmic Technology and AFT Pharmaceuticals.
0
1
4
@BOTU_NZ
Buchanan Ocular Therapeutics Unit
5 years
Only one week left to register for the first OTE on glaucoma therapeutics and receive a discount when registering for the entire OTE Series 2021, so get in quick. You can register by scanning the QR code below.
0
1
2
@CRS_FG_Ocular
CRS Focus Group - Ocular Delivery
5 years
Don't forget our webinar on Wednesday, March 24th, starting at 10 am Eastern, 2 pm GMT! Please note the time! Join us next Wednesday, as we welcome @LauraEnsignPhD! Meeting link: https://t.co/hUUTRawgBY
0
11
23
@IlvaRupenthal
Ilva Rupenthal
5 years
I am super excited to announce that I have been awarded a Humboldt Research Fellowship for Experienced Researchers which will allow me to work on a new dry eye disease eye drop with Professor Philipp Steven at the University of Cologne for the next three years πŸ₯³πŸ₯‚πŸΎ
12
3
80
@BOTU_NZ
Buchanan Ocular Therapeutics Unit
5 years
Congratulations to @GhadaZidan6 and team for this great paper on 3D printed bandage contact lenses just published in the International Journal of Pharmaceutics.
0
2
6
@BOTU_NZ
Buchanan Ocular Therapeutics Unit
5 years
Congratulations to Sanjay and the rest of the @JenOculSurf team. We are honoured to have been involved in this exciting study!
0
1
5
@IlvaRupenthal
Ilva Rupenthal
5 years
Great team effort @BOTU_NZ at the LEGO exhibition today!
0
1
1
@CrsIndian
CRS Indian Chapter
5 years
Introducing our Keynote Speaker 2 - Dr. Justin Hanes, Johns Hopkins University, USA Topic : Drug delivery to the eye - From concept to clinical success. Registration now at https://t.co/DkJET1l1v9!! #CRS_2021 #Drug_Delivery #Nanotech #business_potential #pharmaceutics
1
6
18
@BOTU_NZ
Buchanan Ocular Therapeutics Unit
5 years
Congratulation to Dr Priyanka Agarwal and the rest of the team for a great review article on "Formulation Considerations for the Management of Dry Eye Disease"πŸ‘ https://t.co/1KiGlmeBn1 #annotated
Tweet card summary image
mdpi.com
Dry eye disease (DED) is one of the most common ocular surface disorders characterised by a deficiency in quality and/or quantity of the tear fluid. Due to its multifactorial nature involving several...
0
1
5